← Back to Clinical Trials
RecruitingNCT06491615

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

◆ AI Clinical Summary

The eyeGENE program is a national research resource that collects genetic information, medical data, and DNA samples from people with inherited eye diseases. Since 2007, this registry has helped researchers better understand and develop treatments for rare inherited vision conditions. Your participation helps advance research that could benefit people with eye diseases for years to come.

Key Objective:This study benefits researchers by expanding a comprehensive database and DNA repository that accelerates the discovery of genetic causes and potential treatments for rare inherited eye diseases.

Who to Consider:People diagnosed with rare inherited eye conditions who want to contribute to genetic research and help advance understanding of vision disorders should consider enrolling.

Trial Parameters

ConditionInherited Ophthalmic Diseases
SponsorNational Eye Institute (NEI)
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment1,000
SexALL
Min Age1 Day
Max Age120 Years
Start Date2024-07-12
Completion2054-06-27

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases. These findings helped them create better treatments. Now researchers want to expand eyeGENE (Registered Trademark) to include more people for certain eye diseases. Objective: To collect information and DNA samples for the study of eye diseases. * Primary objective --To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual * Secondary objectives * To enhance recruitment for clinical trials and investigations in inherited eye diseases * To establish genotype-phenotype correlations for rare eye diseases Eligibility: People of any age with certain eye diseases. These can include aniridia; Best disease; blue-cone monochromacy; corneal dystrophy; and disorders of pigmentation, such as albinism. Relatives unaffected by the eye disease of interest may also be needed. Design: Researchers will select participants based on their diagnosis. The data may include images and test results from eye exams. Participants will provide a sample of saliva. They will receive a kit with written instructions. They will spit in a tube and mail it to the NIH. Participants may be asked to provide a blood sample. The blood may be drawn at the NIH or at a local clinic. The eyeGENE (Registered Trademark) repository will offer researchers data about the participants eye conditions. The data may include pictures of their eyes, results of the genetic testing, and history of other diseases. Researchers will be able to see data such as age and gender, but they will not see names, dates of birth, or contact information.

Eligibility Criteria

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: The participant must present with characteristics consistent with one of the following diagnoses: * Aniridia * Best disease * Blue-cone monochromacy * Corneal dystrophy * Other hypopigmentation disorder affecting vision (e.g., Oculocutaneous and ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome) OR The participant must be a direct, close relative of an affected participant. OR A participant who also participated in the eyeGENE Stage 1 protocol who may benefit from further genetic testing. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Those with impaired decision-making capability who do not have a legally-authorized representative. * Those unable to provide a saliva sample OR have any disease or condition that makes it unsafe for a subject to provide a suitab

Related Trials